Kymera Therapeutics (KYMR) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
May 3, 2022 7:00 AM EDTIRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring
Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs
Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader clinical opportunities; IND filing planned for 2H22
March 31, 2022 cash balance of approximately $523 million, providing cash runway into 2025
Company to hold quarterly results call at 8am... More
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
May 3, 2022 7:00 AM EDTIRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring
Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs
Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader clinical opportunities; IND filing planned for 2H22
March 31, 2022 cash balance of approximately $523 million, providing cash runway into 2025
Company to hold quarterly results call at 8am... More
